The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...

and Vitamin B17 is used in medication to counter cancer. B17 tablets with apricot seed extract are available in Australia and in the US. All the information you need is available on the ...

Cassava Sciences has officially stopped the development of its investigational drug simufilam in Alzheimer’s disease after it failed to show benefit in a second Phase III trial. The company is ...

Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation. As the company prepares to release trial results, Ben Hargreaves finds that ...

Cassava Sciences' pivot to TSC via a Yale license deal for simufilam addresses both new indications and reputation issues but faces significant clinical and market challenges. Preclinical studies ...

Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an issued US method of treatment patent for potential treatment with ...